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Inborn errors of metabolism (IEM) are rare conditions, with an overall 
incidence of 1 per 1000 births. Approximately 40-60% of IEM cases 
present with epilepsy as one of the main clinical presentations of 
the disease. A substantial number of these patients require timely 
and accurate diagnosis, besides specific treatment to prevent the 
irreversible outcomes.
Materials & Methods
In this two-year retrospective study, a total of 128 patients with 
documented neurometabolic disorders were selected and evaluated 
in Mofid Children Hospital of Tehran, Iran, using a questionnaire to 
investigate the prevalence of epilepsy and seizure phenotypes. The 
collected data were evaluated in SPSS version 23.
Results
Seizure was reported in 49% (63/128) of the patients. A single episode 
of seizure occurred in 7 (7%) patients. The prevalence of epilepsy 
was estimated at 42% (54/128). The most common seizure types were 
generalized tonic-clonic (43%), tonic (22%), and myoclonic (10%), 
respectively. Epilepsy was refractory in 30% (16/54) of the patients, 
and the mean number of administered anti-seizure drugs for refractory 
cases was 3.2. Overall, 50% of refractory cases had mixed-type seizures, 
and 25% had generalized tonic-clonic and myoclonic seizures.
Conclusion
Neurometabolic disorders are rare, but treatable causes of epilepsy. A 
considerable number of patients (42%) in the current study presented 
with epilepsy as a clinical feature of IEM.
Keywords: Inborn errors of metabolism; Neurometabolic disorders; 
Epilepsy
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Introduction
Neurometabolic disorders comprise a 
heterogeneous group of genetic defects, which 
interrupt biochemical pathways via three main 
mechanisms: 1) enzymatic dysfunction; 2) 
disturbance of cellular transmembrane transport; 
and 3) mitochondrial dysfunction. Inborn errors 
of metabolism (IEM) are rare conditions, with 
an overall incidence of 1 per 1000 births. They 
present with diverse clinical phenotypes, but often 
have neurological presentations. Epilepsy is a 
more common presentation of IEM, which occurs 
in approximately 40-60% of IEM cases as one of 
the main neurological signs (1-12).
In a previous study, which aimed to elucidate the 
genetic architecture of IEM involving epilepsy or 
seizure, a total of 880 human genes were identified. 
It was found that 373 (42%) genes were associated 
with IEM, and a substantial number (26%; 97/373) 
had specific treatments (13). In addition, various 
clinical patterns may be associated with IEM, 
ranging from occasional seizures triggered by 
epilepsy to epileptic encephalopathy. Seizure 
type may be a valuable clue for determining the 
underlying etiology (14-17).
Materials & Methods 
This descriptive cross-sectional study was 
performed on patients with a documented diagnosis 
of neurometabolic disorders from September 2017 
to May 2019. Patients were selected and evaluated 
in Mofid Children Hospital, Tehran, Iran. Diagnosis 
was confirmed according to the patient’s clinical 
history and confirmed by genetic studies in the 
majority of cases. 
The required information for this study was extracted 
from the patients’ archived documents, using a 
prepared questionnaire. The questionnaire included 
demographic data, pre/perinatal history, family 
history and consanguinity, clinical presentations 
of the disease, seizure characteristics, paraclinical 
findings, treatment response, and disease course; 
other supplementary data were also documented. 
Paraclinical evaluation was performed based on 
the speculated diagnosis. The basic diagnostic tests 
included brain magnetic resonance imaging (MRI), 
brain magnetic resonance spectroscopy (MRS), 
metabolic screening tests, and urine organic acid 
test, while the specific diagnostic tests included 
enzymatic assay or specific investigations. 
Definite diagnosis was confirmed via direct 
sequencing in the majority of cases and whole 
exome sequencing in others. Data were analyzed in 
SPSS version 23. Different diseases were identified 
in the patients (31 disease types). Consequently, 
for the ease of study and investigation, they were 
categorized into six main groups according to 
the Society for the Study of IEM (SSIEM 2012) 
guidelines: 1) amino acid metabolism defects; 2) 
lysosomal disorders; 3) peroxisomal disorders; 4) 
mitochondrial disorders; 5) fatty acid metabolism 
defects; and 6) transmembrane transport defects.
Results
A total of 128 patients with a documented diagnosis 
of neurometabolic disorders were enrolled in this 
study. Based on the results, 59% of the subjects 
were male, and 41% were female. The mean age of 
81
An Approach to Neurometabolic Epilepsy in Children with an Underlying Neurometabolic Disorder
Iran J Child Neurol. Spring  2020 Vol. 14 No. 2
subjects in the first visit was 4.94±0.54 years. Also, 
the mean age of initial symptom presentation was 
2.55±0.44 years. The final diagnosis was established 
at the age of 5.1±0.53 years. Overall, 74% of the 
patients were children of consanguineous parents. 
Similar disease presentations were reported in 30% 
of patients with a family history of the disease. 
Direct gene sequencing was the leading method 
of definite diagnosis in 71% of cases, while whole 
exome sequencing was performed in 22% of 
cases. Also, clinical findings, neuroimaging, and 
metabolic screening were used for the definite 
diagnosis of 7% of cases. 
The prevalence of each disease category was as 
follows: amino acid metabolism defects, 12%; 
lysosomal disorders, 64%; peroxisomal disorders, 
9%; mitochondrial disorders, 14%; fatty acid 
metabolism defects (one patient with carnitine 
deficiency), 0.5%; and transmembrane transport 
defect (one patient with Menkes disease), 0.5% 
(Tables 1-4).
Seizure was reported in 49% (63/128) of the 
patients. A single episode of seizure was reported 
in 7 (7%) patients. Seizure was triggered by 
fever in five patients, by gastroenteritis without 
fever in one patient (glutaric aciduria type I), and 
unprovoked in two patients (L2-hydroxyglutaric 
aciduria and pyruvate dehydrogenase deficiency) 
(Table 5).
 The prevalence of epilepsy was 42% (54/128) 
among patients. According to the history of 
seizure type, focal onset was reported in 25% of 
the patients. Seizure was generalized in 47% of 
cases. However, the type of seizure onset was not 
determined because of remote occurrence, recall 
bias, and lack of medical documentation. The most 
common seizure types were generalized tonic-
clonic (GTC) (43%), tonic (22%), and myoclonic 
(10%), respectively. 
The initial electroencephalography (EEG) was 
inaccessible in 30% of the patients. There was 
no abnormal finding in 40% of cases, while 60% 
had abnormal, but not characteristic findings 
(e.g., spike-and-wave discharges and random or 
occasional epileptic discharges). Epilepsy was 
refractory in 30% (16/54) of cases, and the mean 
number of administered anti-seizure drugs for 
refractory cases was 3.2. Overall, 50% of refractory 
cases had mixed-type seizures, while 25% had 
GTC and myoclonic seizures; other seizure types 
constituted the minority. The characteristics of 
epilepsy in each group are presented separately 
in Table 6. The most commonly administered 
anti-seizure drugs were primidone, phenobarbital, 
clobazam, and levetiracetam, respectively.
82
An Approach to Neurometabolic Epilepsy in Children with an Underlying Neurometabolic Disorder
Iran J Child Neurol. Spring  2020 Vol. 14 No. 2












Sulfite oxidase deficiency 1
L2-hydroxyglutaric aciduria 3
Total 15
Table 2. Diseases reported in group 2
Disease Number of patients
Metachromatic leukodystrophy 6
Krabbe disease 2
Niemann-Pick disease type C 59
Late-onset GM1 gangliosidosis 1
Juvenile GM1 gangliosidosis 3
Tay-Sachs disease 3
Sandhoff disease 3
Late-onset GM2 gangliosidosis 4
Sanfilippo syndrome 1
Total 82
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Table 4. Patients categorized in group 4
Number of patients Disease
4
Mitochondrial complex 1 
defect
3
Mitochondrial complex 2 
defect
1
Mitochondrial complex 3 
defect
1











Table 5. Seizures triggered by fever
Disease













3.5 years Single episode - -
Juvenile GM1 gangliosidosis 2.5 years Single episode - Regression 
Juvenile GM2 gangliosidosis 11 years Single episode - Regression 
Childhood 
adrenoleukodystrophy 5 years Single episode
-
Adrenoleukodystrophy 
symptoms after two years 
Pyruvate dehydrogenase 
deficiency
18 months Refractory 3
Ataxia and metabolic 
crisis
Kearns-Sayre syndrome 18 months Single episode -
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Table 6. Epilepsy characteristics in the groups
Epilepsy prevalence Refractory epilepsy Number of refractory cases
Group 1 7/15 (46%) 2/7 (28%)
Asparagine synthetase deficiency
Biotinidase deficiency
Group 2 43/82 (52%) 10/43 (23%)
Niemann-Pick disease type C (8)
Metachromatic leukodystrophy (1)
Juvenile GM2 gangliosidosis
Group 3 3/11 (27%) 1/3 (33%) Adrenoleukodystrophy





Although IEM is a rare cause of epilepsy, seizure 
and epilepsy are common in IEM (40-60%). The 
prevalence of seizure and epilepsy in the current 
study was 42%, which is compatible with previous 
studies. Management of epilepsy in IEM cannot 
be accomplished unless the underlying etiology 
is recognized and treated. Pyridoxine-dependent 
epilepsy and biotinidase deficiency are some 
paramount examples (9). Many of these disorders 
are amenable to specific treatment (97/373), and 
timely and accurate diagnosis is necessary to 
prevent the irreversible outcomes. In the present 
study, refractory epilepsy was controlled via 
biotin administration in patients with biotinidase 
deficiency (20 mg/day), and the administered anti-
seizure drugs were successfully tapered off (four 
drugs tapered to two). The EEG findings did not 
indicate any clinical resolution, and the patients 
were responsive to pulse methylprednisolone 
administration (30 mg/kg/d for five days).
A wide range of clinical and EEG patterns 
of epilepsy may be suitable clues for IEM 
diagnosis, including burst suppression pattern, 
hypsarrhythmia, modified hypsarrhythmia 
associated with myoclonus, and paroxysmal 
responses to photic stimulation at low frequencies. 
However, such findings were not evaluated in our 
study due to several reasons. First, our hospital is a 
tertiary referral center, where most patients are not 
visited immediately after the disease onset, and we 
usually miss some initial critical data. Second, poor 
or unqualified documentation in some cases might 
be influential in the results. Third, the majority of 
patients in our study had Niemann-Pick disease type 
C (NPC). Since there was no possible access to the 
filter paper method of screening in other centers 
and our center is a referral center for lysosomal 
diseases, there is a possibility of selection bias. 
Finally, this was a retrospective study. Therefore, 
to obtain all the required data, a prospective study 
must be designed.
Seizures may present with numerous clinical 
features. They may be initial and cardinal signs, 
occasional events triggered by fever or acute 
illness, or even a single event with no recurrence. 
In the current study, seizure provoked by fever 
was the initial presentation in seven patients. 
Although it is not common, in the context of febrile 
seizures, it is necessary to check the patient’s full 
medical background, family history, and physical 
examinations to explore possible metabolic 
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etiologies (18-20). 
Reports of refractory epilepsy in the literature are 
contradictory due to different definitions, different 
etiologies, and different settings. However, the 
overall prevalence ranges from 20% to 40%. 
Attention must be paid to the patient’s partial 
or poor response to anti-seizure drugs in the 
presence of an underlying metabolic etiology. 
The prevalence of refractory epilepsy was 30% 
in the present study according to the International 
League against Epilepsy (ILAE) 2017 definition 
of refractory epilepsy, which is not higher than 
the prevalence reported in previous studies for 
its etiology. There was a considerable difference 
between the prevalence of epilepsy (16%) and 
refractory epilepsy (100%) in patients with 
mitochondriopathies, which are categorized as 
energy metabolism disorders based on SSIEM 
2012.
According to a study by Birute et al., extensive 
search of OMIM, PubMed, and MEDLINE 
databases showed that the majority of IEM cases 
(87%) with epilepsy are autosomal recessive, 
while 6% are mitochondrial, 4% are X-linked, and 
3% are autosomal dominant. The prevalence of 
consanguineous marriage was 74% in our patients, 
which potentially increases the risk of IEM and 
highlights the importance of promoting public 
knowledge and preventive policies.
In Conclusion
Neurometabolic disorders are rare, but treatable 
causes of epilepsy and require timely and accurate 
diagnosis, besides specific treatment to prevent the 
irreversible outcomes.
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